SEC Company Response from Dominari Holdings Inc. (DOMH) (CIK 0000012239) (DOMH) — Jun 12, 2020
Dominari Holdings Inc. (DOMH) (CIK 0000012239)
Date: June 12, 2020 · CIK: 0000012239 · Accession: 0001213900-20-014808
AI Filing Summary & Sentiment
File numbers found in text: 333-238172
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences Re: AIKIDO PHARMA INC. Amendment No. 1 to Registration Statement on Form S-3 Filed June 8, 2020 File No. 333-238172
Dear Ada:
AIkido Pharma Inc. (the “Company”, “we”, “us” or “our”) hereby transmits our response to the comment letter received by us from the staff (the “Staff”) of the Securities and Exchange Commission, dated June 11, 2020, regarding the Company’s Amendment No. 1 to Registration Statement on Form S-3 previously filed on June 8, 2020 (the “Registration Statement”) for the Staff’s review.
For the Staff’s convenience, we have repeated below the Staff’s comment in bold, and have followed the comment with the Company’s response.
Amendment No. 1 to Registration Statement on Form S-3
Licenses, Page 5
1. We note your response to our prior comment 2. Please revise to disclose the aggregate future potential milestone payments, a range for the percentage of net sales royalty not to exceed ten percent and a range for the minimum annual royalty.
RESPONSE: In response to the Staff’s comment, we revised the disclosure on page 5 of Registration Statement.
We thank the Staff for its review of the foregoing. If you have further comments, we ask that you forward them by electronic mail to our counsel, Robert F. Charon, Esq. of Ellenoff Grossman & Schole LLP at rcharon@egsllp.com or by telephone at (212) 370-1300.
Very truly yours,
/s/ Anthony Hayes
Show Raw Text
CORRESP
1
filename1.htm
AIkido Pharma Inc.
One Rockefeller Plaza, 11th Floor
New York, New York 10020
June 12, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ada D. Sarmento
Re:
AIKIDO PHARMA INC.
Amendment No. 1 to Registration Statement
on Form S-3
Filed June 8, 2020
File No. 333-238172
Dear Ada:
AIkido Pharma Inc. (the
“Company”, “we”, “us” or “our”) hereby transmits our
response to the comment letter received by us from the staff (the “Staff”) of the Securities and Exchange Commission,
dated June 11, 2020, regarding the Company’s Amendment No. 1 to Registration Statement on Form S-3 previously filed on June
8, 2020 (the “Registration Statement”) for the Staff’s review.
For the Staff’s convenience,
we have repeated below the Staff’s comment in bold, and have followed the comment with the Company’s response.
Amendment No. 1 to Registration Statement on Form
S-3
Licenses, Page 5
1. We note your response to our prior comment
2. Please revise to disclose the aggregate future potential milestone payments, a range for the percentage of net sales royalty
not to exceed ten percent and a range for the minimum annual royalty.
RESPONSE: In response to the Staff’s
comment, we revised the disclosure on page 5 of Registration Statement.
We thank the Staff for
its review of the foregoing. If you have further comments, we ask that you forward them by electronic mail to our counsel, Robert
F. Charon, Esq. of Ellenoff Grossman & Schole LLP at rcharon@egsllp.com or by telephone at (212) 370-1300.
Very truly yours,
/s/ Anthony Hayes
Anthony Hayes, Chief Executive Officer
AIkido Pharma Inc.
cc:
Ellenoff Grossman & Schole LLP